Adicon Holdings Limited (SEHK:9860) agreed to acquire Suzhou Yuande Weikang Biomedical Co., Ltd. from CHEN Jun for approximately CNY 200 million on May 6, 2025. The consideration consists of 14.51 million common equity of Adicon Holdings Limited to be issued for common equity of Suzhou Yuande Weikang Biomedical Co., Ltd. Adicon Holdings Limited will pay an earnout/contingent payment common equity.
The transaction is subject to approval by regulatory board / committee.
Adicon Holdings Ltd is an investment holding company principally engaged in the provision of independent clinical laboratory (ICL) services. The Company primarily provides testing services to hospitals, medical institutions, medical examination centers, consumers, pharmaceutical companies and contract research organizations (CROs). The Company's inspection services mainly include routine tests, esoteric tests, clinical immunologic testing, clinical chemistry testing, clinical molecular biology testing, pathology testing and others testing. The Company is also engaged in the sales of medical testing equipment. The Company principally conducts its businesses in the domestic market.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
